Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8440415 | European Journal of Cancer | 2018 | 8 Pages |
Abstract
This largest IPD analysis of mCRC trials to date demonstrates an improved survival in synchronous mCRC patients after PTR. These results may be subject to bias since reasons for (non)resection were not available. Until results of ongoing RCTs are available, both upfront PTR followed by systemic treatment and upfront systemic treatment are considered appropriate treatment strategies.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
K.L. van Rooijen, Q. Shi, K.K.H. Goey, J. Meyers, V. Heinemann, E. Diaz-Rubio, E. Aranda, A. Falcone, E. Green, A. de Gramont, D.J. Sargent, C.J.A. Punt, M. Koopman,